Oncology

Inhibiting the protein PARP 14 shows promise in stopping uncontrolled cancer cell growth.

Research may lead to targeted therapies with reduced side effects.

Tumor necrosis factor alpha inhibitor can also treat autoimmune diseases such as rheumatoid arthritis and psoriasis.

Study finds inhibition of the NOTCH4 signal may be a promising target to prevent the growth and spread of cancer.

Novel method may reduce the length of treatment time and decrease side effects.

Keytruda treats patients with metastatic non-small cell lung cancer whose disease has progressed despite other treatment methods.

Therapy with binimetinib and ribociclib shows significant clinical activity in NRAS-mutant melanoma patients.

Top cancer-related news from the past week.

Economic development and urbanization factors influence cancer incidence growth.

New therapeutic target may decrease breast cancer risk.

Treatment with dabrafenib and trametinib extends patient survival more than 2 years.

Research offers enhanced method to assess effects of cancer drugs on normal and healthy cells.

New approach may stop growth and kill cancer cells.

Luteolin may carry significant anti-tumor effects.

Patients treated with atezolizumab lived an average of 7.7 months longer than people treated with docetaxel chemotherapy.

Desmoplasmic melanoma possesses a mutation that protects tumors from destruction by the immune system.

Top news of the week in oncology drug development.

Discovery could lead to treatments that stop cancer recurrence.

More than just biological factors can affect patient outcomes.

Top stories of the week on Specialty Pharmacy Times.

Expansion covers patients who have greater than 30% myeloblasts.

Average time for withdrawals in colonoscopies came in at approximately 8.6 minutes.

Intralesional interleukin-2 shows promise in cutaneous melanoma metastases.

Technology may help improve patient outcomes through enhanced personalized medicine.

Nanopore technology may soon be adapted for early disease detection.

Bristol-Myers Squibb will take part in Leerink Partners Immuno-Oncology Roundtable on October 1.

Findings could eliminate need for weeks of treatments that carry severe side effects.

Research may help tailor treatments to individual patients.

Average reimbursement for Part B oncology drugs is 52% higher in 340B hospitals than in community cancer clinics.

Treatment seeks to reverse chemotherapy resistance caused by P-glycoprotein.